FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3087498123> ?p ?o ?g. }

• W3087498123 endingPage "15.e4" @default.
• W3087498123 startingPage "6" @default.
• W3087498123 abstract "We evaluated maintenance nanoparticle albumin-bound (nab) paclitaxel in the treatment of advanced squamous non-small-cell lung cancer.Patients with treatment-naive squamous non-small-cell lung cancer received four 21-day cycles of nab-paclitaxel 100 mg/m2 on days 1, 8, 15 plus carboplatin area under the curve 6 on day 1 as induction therapy. Patients without disease progression after induction were randomized 2:1 to maintenance nab-paclitaxel 100 mg/m2 (days 1 and 8 every 21 days) plus best supportive care (BSC) or BSC alone. The primary endpoint was progression-free survival (PFS). Secondary endpoints included safety and overall survival (OS).Overall, 420 patients had received induction therapy; 202 (nab-paclitaxel plus BSC, 136; BSC, 66) had received maintenance therapy. Enrollment was discontinued after a preplanned interim futility analysis (patients could remain in the study at the investigator's discretion). The median PFS was 3.12 months for nab-paclitaxel plus BSC and 2.60 months for BSC; the difference was not statistically significant (hazard ratio [HR], 0.85; 95% confidence interval [CI], 0.61-1.19; P = .36). The median OS (median follow-up, 24.2 months) was 17.18 months for nab-paclitaxel plus BSC and 12.16 months for BSC (HR, 0.70; 95% CI, 0.48-1.02; nominal P = .07). An updated analysis (median follow-up, 28.4 months) revealed a median OS of 17.61 months for nab-paclitaxel plus BSC and 12.16 months for BSC (HR, 0.68; 95% CI, 0.47-0.98; nominal P = .037). The most frequent grade 3 and 4 treatment-emergent adverse events for the entire study were neutropenia (53.1% [nab-paclitaxel plus BSC] vs. 50.0% [BSC]) and anemia (33.1% [nab-paclitaxel plus BSC] vs. 32.3% [BSC]). Only peripheral neuropathy had occurred in ≥ 5% of patients during maintenance therapy (13.1%; nab-paclitaxel plus BSC).The results of the ABOUND.sqm did not meet the primary endpoint of PFS. An updated OS analysis revealed a trend favoring nab-paclitaxel plus BSC." @default.
• W3087498123 created "2020-09-25" @default.
• W3087498123 creator A5008290108 @default.
• W3087498123 creator A5013804417 @default.
• W3087498123 creator A5014364032 @default.
• W3087498123 creator A5016913535 @default.
• W3087498123 creator A5018054038 @default.
• W3087498123 creator A5026408052 @default.
• W3087498123 creator A5028801628 @default.
• W3087498123 creator A5029723322 @default.
• W3087498123 creator A5031420337 @default.
• W3087498123 creator A5035987792 @default.
• W3087498123 creator A5040180882 @default.
• W3087498123 creator A5045384053 @default.
• W3087498123 creator A5049504224 @default.
• W3087498123 creator A5054486965 @default.
• W3087498123 creator A5063403710 @default.
• W3087498123 creator A5065865976 @default.
• W3087498123 creator A5072753291 @default.
• W3087498123 creator A5078629724 @default.
• W3087498123 creator A5082130570 @default.
• W3087498123 creator A5087929151 @default.
• W3087498123 date "2021-01-01" @default.
• W3087498123 modified "2023-10-17" @default.
• W3087498123 title "Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non–Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical Trial" @default.
• W3087498123 cites W2005244154 @default.
• W3087498123 cites W2112621029 @default.
• W3087498123 cites W2122798232 @default.
• W3087498123 cites W2136023414 @default.
• W3087498123 cites W2148367564 @default.
• W3087498123 cites W2149564448 @default.
• W3087498123 cites W2164067249 @default.
• W3087498123 cites W2796582438 @default.
• W3087498123 cites W2892640821 @default.
• W3087498123 cites W3017322331 @default.
• W3087498123 doi "https://doi.org/10.1016/j.cllc.2020.09.007" @default.
• W3087498123 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33097414" @default.
• W3087498123 hasPublicationYear "2021" @default.
• W3087498123 type Work @default.
• W3087498123 sameAs 3087498123 @default.
• W3087498123 citedByCount "6" @default.
• W3087498123 countsByYear W30874981232022 @default.
• W3087498123 countsByYear W30874981232023 @default.
• W3087498123 crossrefType "journal-article" @default.
• W3087498123 hasAuthorship W3087498123A5008290108 @default.
• W3087498123 hasAuthorship W3087498123A5013804417 @default.
• W3087498123 hasAuthorship W3087498123A5014364032 @default.
• W3087498123 hasAuthorship W3087498123A5016913535 @default.
• W3087498123 hasAuthorship W3087498123A5018054038 @default.
• W3087498123 hasAuthorship W3087498123A5026408052 @default.
• W3087498123 hasAuthorship W3087498123A5028801628 @default.
• W3087498123 hasAuthorship W3087498123A5029723322 @default.
• W3087498123 hasAuthorship W3087498123A5031420337 @default.
• W3087498123 hasAuthorship W3087498123A5035987792 @default.
• W3087498123 hasAuthorship W3087498123A5040180882 @default.
• W3087498123 hasAuthorship W3087498123A5045384053 @default.
• W3087498123 hasAuthorship W3087498123A5049504224 @default.
• W3087498123 hasAuthorship W3087498123A5054486965 @default.
• W3087498123 hasAuthorship W3087498123A5063403710 @default.
• W3087498123 hasAuthorship W3087498123A5065865976 @default.
• W3087498123 hasAuthorship W3087498123A5072753291 @default.
• W3087498123 hasAuthorship W3087498123A5078629724 @default.
• W3087498123 hasAuthorship W3087498123A5082130570 @default.
• W3087498123 hasAuthorship W3087498123A5087929151 @default.
• W3087498123 hasBestOaLocation W30874981231 @default.
• W3087498123 hasConcept C121608353 @default.
• W3087498123 hasConcept C126322002 @default.
• W3087498123 hasConcept C141071460 @default.
• W3087498123 hasConcept C143998085 @default.
• W3087498123 hasConcept C168563851 @default.
• W3087498123 hasConcept C203092338 @default.
• W3087498123 hasConcept C207103383 @default.
• W3087498123 hasConcept C2776256026 @default.
• W3087498123 hasConcept C2776694085 @default.
• W3087498123 hasConcept C2777292972 @default.
• W3087498123 hasConcept C2778239845 @default.
• W3087498123 hasConcept C2780739268 @default.
• W3087498123 hasConcept C2781451048 @default.
• W3087498123 hasConcept C44249647 @default.
• W3087498123 hasConcept C61943457 @default.
• W3087498123 hasConcept C71924100 @default.
• W3087498123 hasConcept C90924648 @default.
• W3087498123 hasConceptScore W3087498123C121608353 @default.
• W3087498123 hasConceptScore W3087498123C126322002 @default.
• W3087498123 hasConceptScore W3087498123C141071460 @default.
• W3087498123 hasConceptScore W3087498123C143998085 @default.
• W3087498123 hasConceptScore W3087498123C168563851 @default.
• W3087498123 hasConceptScore W3087498123C203092338 @default.
• W3087498123 hasConceptScore W3087498123C207103383 @default.
• W3087498123 hasConceptScore W3087498123C2776256026 @default.
• W3087498123 hasConceptScore W3087498123C2776694085 @default.
• W3087498123 hasConceptScore W3087498123C2777292972 @default.
• W3087498123 hasConceptScore W3087498123C2778239845 @default.
• W3087498123 hasConceptScore W3087498123C2780739268 @default.
• W3087498123 hasConceptScore W3087498123C2781451048 @default.
• W3087498123 hasConceptScore W3087498123C44249647 @default.
• W3087498123 hasConceptScore W3087498123C61943457 @default.
• W3087498123 hasConceptScore W3087498123C71924100 @default.

• next